roledumab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 464383323

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = RHD

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| CAS_number = 1174008-79-7

| CAS_number_Ref = {{cascite|correct|CAS}}

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = Z4T52O86QV

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen.{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103 | journal = WHO Drug Information | year = 2010 | url =https://www.who.int/medicines/publications/druginformation/INN_PL103.pdf }}{{cite journal | vauthors = Kaplon H, Reichert JM | title = Antibodies to watch in 2018 | journal = mAbs | volume = 10 | issue = 2 | pages = 183–203 | date = 2018 | pmid = 29300693 | pmc = 5825203 | doi = 10.1080/19420862.2018.1415671 }}

It is currently at Phase III trials for Rh disease.